awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35231826-B9DDD3F6-4CC5-4F78-A2A3-BBE560B2186B
Q35231826-B9DDD3F6-4CC5-4F78-A2A3-BBE560B2186B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35231826-B9DDD3F6-4CC5-4F78-A2A3-BBE560B2186B
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
P2860
Q35231826-B9DDD3F6-4CC5-4F78-A2A3-BBE560B2186B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35231826-B9DDD3F6-4CC5-4F78-A2A3-BBE560B2186B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
966528fce6da87a67c64b3b0add2cb5df3955829
P2860
Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention.